Matrix metalloproteinase (MMP)-2 plays critical roles in tumor development and in the metastasis of multiple cancers, including human oral cavity squamous cell carcinoma (OCSCC). One of the upstream regulators of MMP-2 is FOXM1, which is overexpressed in a microarray dataset of OCSCC. It is interesting that FLJ10540 exhibits similar gene expression profiles with MMP-2 and FOXM1, raising the possibility that these molecules might participate in MMP-2-elicited cancer progression and metastasis of OCSCC. To examine this connection, we first showed that FLJ10540 was significantly overexpressed in OCSCC. A strong FLJ10540 expression was significantly correlated with an advanced tumor node metastasis stage and the cumulative 5-year survival rate. Thus, an elevated FLJ10540 expression is an indicator of poor survival. Functionally, FLJ10540 had the abilities to stimulate cell migration and invasion in oral cancer cells through increased FOXM1 and MMP-2 expressions. Conversely, the depletion of the FLJ10540 expression by small interefering RNAs suppressed the FOXM1 and MMP-2 protein expressions. The suppression of either FLJ10540 or FOXM1 could cause significant inhibition on cell migratory and invasive ability in oral cancer cells. Finally, the immunohistochemical and western blotting analyses of human aggressive OCSCC specimens showed a significant positive correlation among FLJ10540, FOXM1 and MMP-2 expressions. These findings suggest that FLJ10540 is not only an important prognostic factor but also a new therapeutic target in the FLJ10540/FOXM1/MMP-2 pathway for OCSCC treatment.
Matrix metalloproteinase (MMP)-2 plays critical roles in tumor development and in the metastasis of multiple cancers, including human oral cavity squamous cell carcinoma (OCSCC). One of the upstream regulators of MMP-2 is FOXM1, which is overexpressed in a microarray dataset of OCSCC. It is interesting that FLJ10540 exhibits similar gene expression profiles with MMP-2 and FOXM1, raising the possibility that these molecules might participate in MMP-2-elicited cancer progression and metastasis of OCSCC. To examine this connection, we first showed that FLJ10540 was significantly overexpressed in OCSCC. A strong FLJ10540 expression was significantly correlated with an advanced tumor node metastasis stage and the cumulative 5-year survival rate. Thus, an elevated FLJ10540 expression is an indicator of poor survival. Functionally, FLJ10540 had the abilities to stimulate cell migration and invasion in oral cancer cells through increased FOXM1 and MMP-2 expressions. Conversely, the depletion of the FLJ10540 expression by small interefering RNAs suppressed the FOXM1 and MMP-2 protein expressions. The suppression of either FLJ10540 or FOXM1 could cause significant inhibition on cell migratory and invasive ability in oral cancer cells. Finally, the immunohistochemical and western blotting analyses of human aggressive OCSCC specimens showed a significant positive correlation among FLJ10540, FOXM1 and MMP-2 expressions. These findings suggest that FLJ10540 is not only an important prognostic factor but also a new therapeutic target in the FLJ10540/FOXM1/MMP-2 pathway for OCSCC treatment.
Introduction
Head and neck cancer is the sixth most common cancer worldwide and is associated with high rates of recurrence and mortality (Parkin et al., 2005) . In Taiwan, head and neck cancer is the fifth leading cause of death in male cancer patients, causing about 1500 deaths per year (Hardisson, 2003) . Despite research efforts and the development of new therapies, its 5-year survival has not improved over the past four decades (Sudbo and Reith, 2005) . Oral cavity squamous cell carcinoma (OCSCC), a specific type of head and neck cancer, encompasses at least 90% of all oral malignancies (Beenken and Urist, 2003) . The OCSCC is a multifactorial condition with etiological links to a wide range of external carcinogens, including alcohol, tobacco, betel nut, and to certain viral and bacterial infections (Lo et al., 2003) . Although OCSCC is a potentially curable disease in its early stages, its treatment is associated with a plethora of long-term side effects, post-therapeutic complications and a significant decrease in the quality of life (Chandu et al., 2006) . Typically, 50% OCSCC patients have a detectable lymph node involvement at presentation. Patients with lymph node metastasis have a markedly worse prognosis than do patients without metastasis (Kato et al., 2006) .
Tumor metastases are the important steps in determining the aggressive phenotype of human cancers and are the major causes of cancer deaths (Steeg, 2003) . The process of metastasis is very complex and is considered to be a late event in tumorigenesis. Degradation of basement membranes and the stromal extracellular matrix are crucial steps for tumor invasion and metastasis. The matrix metalloproteinases (MMPs) are part of a large family of zinc-and calcium-dependent proteolytic enzymes that have been repeatedly implicated in migration, invasion and metastasis (Munshi et al., 2002; Kamat et al., 2006; Jezierska and Motyl, 2009) . MMP-2 is capable of degrading collagen IV, a major component of the basement membrane that serves as a barrier between tissue compartments (Werner et al., 2002) . MMP-2 is also closely associated with tumor progression and metastasis in human OCSCC; specifically, they have been shown to be localized to the advancing tumor front and are implicated in metastatic dissemination (Hong et al., 2000) . The elevated expression of the MMP-2 immunoreactive protein is correlated with a poor prognosis in OCSCC (Ruokolainen et al., 2004; Gao et al., 2005; Patel et al., 2007) . In addition, MMP-2 expression could be regulated by several transcription factors, including YB-1 (Mertens et al., 1997) , Sp1 (Qin et al., 1999) , p53 (Bian and Sun, 1997) , Stat3 (Xie et al., 2004) and FOXM1 (Dai et al., 2007) ; however, the molecular mechanisms by which MMP-2 is activated and controls tumor metastasis in OCSCC remain elusive.
In OCSCC, it is crucial to determine the molecular changes associated with metastasis. The application of this knowledge will lead to a better understanding of the biology of this tumor, and will provide prognostic information for defining subgroups of patients with an unfavorable prognosis as potential candidates for adjuvant or novel therapies. FLJ10540 has several names, including CEP55 (Fabbro et al., 2005) , C10orf3 (Sakai et al., 2006) and URCC6. FLJ10540 is overexpressed in human colon cancer (Sakai et al., 2006) , in hepatocellular carcinoma (Chen et al., 2007) and in lung cancer (Chen et al., 2009) , suggesting that it may function as an oncogene in tumor development. In addition, we previously showed that the overexpression of FLJ10540 contributes to cellular transformation through the activation of PI3K/AKT (Chen et al., 2007) . However, no systematic analysis of the FLJ10540 expression and its clinicopathological and functional significance has been carried out for OCSCC.
In this study, an increased FLJ10540 expression was detected in OCSCC patients using semi-quantitative reverse transcriptase (RT)-PCR, quantitative-RT-PCR, western blotting and immunohistochemistry. In addition, the FLJ10540 overexpression was not only correlated with aggressiveness and poor prognosis of OCSCC but also contributed to the upregulated protein expressions of FOXM1 and MMP-2 and to MMP-2 activity for enhancing the migration and invasion of oral cancer cells. Conversely, a small interfering RNA (siRNA)-mediated repression of FLJ10540 or FOXM1 reversed these effects on the MMP-2 protein expression and MMP-2 activity to suppress cell motility. Furthermore, an increased FLJ10540 was not only co-localized with FOXM1 but was also positively correlated with FOXM1 and MMP-2 expressions in samples collected from patients with aggressive OCSCC. These results indicate that FLJ10540 may be a critical regulator in the metastasis of tumors in OCSCC, and that FLJ10540 is an important marker and therapeutic target for patients with OCSCC.
Results

FLJ10540 is overexpressed in OCSCC tissues
Using the concept of syn-expression, genes belonging to the same pathway or to a similar function often show the same regulatory profiles under a variety of biological situations (Niehrs and Pollet, 1999; Yu et al., 2005) . Hence, to map the upstream regulator(s) participating in MMP-2-elicited cancer progression of OCSCC, we used a publicly accessible microarray dataset of squamous cell carcinoma of the head and neck to gain an insight into the functional concordance of co-expressed genes. Of the B2000 overexpressed genes reported in the squamous cell carcinoma of the head and neck microarray study (Ginos et al., 2004) , the only overexpressed and reported upstream regulator of MMP-2 is FOXM1. Using MMP-2 and FOXM1 as templates, we revealed a group of genes that overexpressed in tumor tissues than in normal tissues, and FLJ10540 was chosen for our study. FLJ10540 exhibits a positive correlation with the mRNA expression level of MMP-2 (r ¼ 0.55, Po0.001) and FOXM1 (r ¼ 0.53, Po0.001). This analysis raises the possibility that these three molecules are functionally linked or are in the same pathway. However, the regulation of FOXM1 and MMP-2 has only been reported in glioma cells (Dai et al., 2007) and has not been explored in OCSCC. Therefore, we aimed at determining whether there is a specific signaling pathway, FLJ10540/FOXM1/MMP-2, in OCSCC.
To study the potential role of FLJ10540 in the pathogenesis of OCSCC, we first asked whether the level of FLJ10540 mRNA was elevated in primary tumor tissues. Total RNA from 12 tumor samples and from matched adjacent non-cancerous tissues was extracted and analysed for the FLJ10540 mRNA expression by semi-quantitative RT-PCR. FLJ10540 was highly expressed in the tumor specimens, with a positive rate of 83% (10/12), whereas the adjacent noncancerous tissues expressed low levels of FLJ10540 (Figure 1a) . Moreover, the same samples were also applied to quantitative-RT-PCR analysis, and the average expression level of FLJ10540 in OCSCC was fourfold (Po0.05) higher than that in adjacent noncancerous oral tissue samples as analysed by boxplot (Figure 1b) . We next verified the expression of FLJ10540 in representative and paired freshly frozen tumor and adjacent non-cancerous samples by western blotting, using affinity-purified rabbit anti-human FLJ10540 polyclonal antibodies. Our data indicate that the level of FLJ10540 was increased in the tumor samples than in the paired adjacent non-cancerous tissues ( Figure 1c ). Our western blotting results are consistent with the observed mRNA expression of FLJ10540 in OCSCC patients.
To evaluate where the FLJ10540 protein is expressed in normal oral mucosa, we performed immunohistochemisty. The immunohistochemistry staining revealed that a very weak or no staining of FLJ10540 was observed in the cytoplasm in normal oral mucosa (Figure 2A, a) . This staining was not observed when an anti-FLJ10540 antibody was pre-incubated with protein corresponding to a portion of FLJ10540 (data not shown). Next, to investigate the clinical implications of FLJ10540 in OCSCC, an immunohistochemical analysis was also carried out to determine the expression and distribution of FLJ10540 in 256 human OCSCC tissues, and the results were compared with the level of FLJ10540 immunoreactivity in adjacent non-cancerous tissues. The representative results of FLJ10540 immunostaining of OCSCC are shown in Figure 2A . First, a prominent staining was observed in the tumor samples (Figures 2Ad-h ) compared with that in the adjacent non-cancerous tissues, which showed a weak but detectable FLJ10540 expression (Figures 2Ab and c) . Second, in the tumor samples, the FLJ10540 expression was positively correlated with the tumor stage and the node stage of the tumor cells (Figures 2Ad-k) . Notably, we found that FLJ10540 was largely localized in the cytoplasm of both tumor samples (Figures 2Ad-g ) and adjacent non-cancerous tissues (Figure 2Ab ). In some cases, however, the tumor tissues and the adjacent noncancerous tissues showed that FLJ10540 was expressed focally in the nucleus (Figures 2Ac and h) . Moreover, in a few tumor tissues, an FLJ10540 expression was also observed with punctate staining in the cytoplasm (Figure 2Ai ). To investigate whether the increased expression of FLJ10540 was associated with various prognostic factors, such as age, sex and tumor node metastasis (TNM) pathological classification, we classified the patients into two groups on the basis of our immunohistochemical results for FLJ10540: negative or weak expression (À to þ ) and strong expression ( þ þ to þ þ þ ). As shown in Table 1 , those patients with stage 3-4 tumors and lymph node metastasis (N þ ) had a significantly higher expression of FLJ10540 compared with those patients with stage 1-2 tumors (Po0.001) and without lymph node metastasis (NÀ) (Po0.001). Furthermore, TNM stages III and IV were significantly correlated with a strong FLJ10540 expression (Po0.001), whereas no significant difference was observed in terms of the patients' age, sex and histological type at the time of diagnosis between high and low levels of FLJ10540. To further confirm our results, an anti-FLJ10540 antibody from Abnova (Taipei, Taiwan) produced almost the same results. These findings suggest that a highly expressed FLJ10540 could be generally related to the tumor progression of OCSCC.
Survival of OCSCC patients with FLJ10540 expression
As the tumor expression of FLJ10540 was associated with tumor stage, we asked whether FLJ10540 was correlated with patient prognosis. The median follow-up for the 256 patients was 49.3 months (range ¼ 2-141 months). As shown in Figure 2B , an overall survival analysis using the Kaplan-Meier method revealed that the prognosis of those patients with a strong tumor expression of FLJ10540 ( þ þ / þ þ þ ) was significantly poorer than that of patients with a negative or weak tumor FLJ10540 expression (À/ þ ) (Po0.001). A univariate analysis showed that tumor stage (Po0.001), nodal stage (Po0.001), TNM stage (Po0.001) and FLJ10540, each predicted a significantly worse prognosis in OCSCC patients ( Table 2 ). The clinical prognosis was, however, not associated with age, sex or histological type. These results clearly indicated that the 5-year survival and clinical prognosis of OCSCC are associated with the expression of FLJ10540 and suggested that FLJ10540 is a good prognostic factor for OCSCC patients.
FLJ10540 promotes the migration and invasion of oral cancer cells
The association of the tumor overexpression of FLJ10540 was significantly higher in those OCSCC patients with lymph node metastasis (N þ ) than in those without lymph node metastasis (NÀ). This raises the possibility that FLJ10540 promotes metastasis in OCSCC. Therefore, we analysed whether an increased FLJ10540 expression affects metastatic parameters, including migration and invasion. Three different cell types were used to evaluate this possibility. First, FaDu cells stably expressing hemagglutinin (HA)-tagged FLJ10540 were established. An increased FLJ10540 expression was identified in two stable clones compared with that in the vehicle control ( Figure 3a , left panel). These cells were subjected to a Transwell migration and invasion assay. The proliferation rate as determined by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was not significantly different between the vehicle control and the cells expressing FLJ10540 during a 24 h period (data not shown). In addition, the morphology of cells in each group was unchanged. The migratory ability of the FaDu/ FLJ10540 transfectants was approximately 6.5-7.5-fold higher than that of the vehicle controls ( Figure 3a , middle panel). We next carried out an invasion assay using a Matrigel-coated barrier filter (BD Biosciences, Bedford, MA, USA). After 24 h of incubation in the Matrigel-coated Transwell chamber (BD Biosciences), the FaDu/FLJ10540 transfectants had invaded the basement membrane material and passed through the pores to reach the underside of the filter. Similarly, the FaDu/FLJ10540-expressing cells showed an 8-9-fold higher invasive ability than the vehicle control cells (Figure 3a , right panel). Second, to address whether FLJ10540 could promote cell migration in a tongue squamous cell line, SCC25 cells stably expressing HAtagged FLJ10540 at various levels were characterized using Transwell chambers ( Figure 3b , left panel). The SCC25/FLJ10540 transfectants induced cell migration at a rate that was about 4.5-5-fold higher than that in the vehicle SCC25 cells (Figure 3b , middle panel). Quantitatively speaking, the invasive ability of the SCC25/FLJ10540 transfectants was approximately 8-fold higher than that of the vehicle controls (Figure 3b , right panel). Finally, HA-tagged FLJ10540 transfectants with different expression levels were characterized in Madin-Darby canine kidney (MDCK) cells (Supplementary Figure S1A ) that had been used successfully to evaluate cell motility induced by different genes (Khoury et al., 2005; Olmeda et al., 2007) . Similarly, MDCK/FLJ10540 transfectants could induce cell migration and invasion higher than that by vehicle MDCK cells (Supplementary Figure S1B) . Taken together, these findings support the hypothesis that FLJ10540 promotes cell migration and invasion of cancer cells.
The knockdown of endogenous FLJ10540 expression by siRNAs suppresses oral cancer cell migration and invasion To further explore whether FLJ10540 expression affects cell migration and invasion in human oral cancer cells, we used siRNAs to inhibit endogenous FLJ10540 expression and assayed the migratory and invasive ability of FaDu and SCC25 cells. Two FLJ10540 siRNAs were transfected into FaDu and SCC25 cells for 24 h, followed by western blotting analysis using antibodies against FLJ10540. The data showed a dramatic reduction in the level of FLJ10540 with both siRNAs; moreover, no significant reduction in FLJ10540 (Figure 5a , right panel). To ascertain whether FLJ10540 plays a critical role in the induction of FOXM1, we monitored the regulation of FOXM1 after transfection with FLJ10540-specific siRNAs. As shown in Figure 5b , the mRNA and protein expressions of FOXM1 were clearly reduced in the presence of FLJ10540-siRNAs in the FaDu and HEK293T cells. In contrast, the negative control siRNA had little effect on the cell line. Second, to further elucidate the role of FLJ10540 in regulating FOXM1 transcription, we investigated whether FLJ10540 could regulate FOXM1 promoter activity. We co-transfected the FOXM1 promoter-luciferase constructs into HEK293T cells with Flag-FLJ10540 or with vehicle control in a dose-dependent manner. The data indicated that a significant activation of the FOXM1 promoter was detected in Flag-FLJ10540 transfectants than in the vehicle control (Figure 5c , left panel). Conversely, the FOXM1 promoter activity was decreased when the FLJ10540 expression was knocked down by FLJ10540-siRNAs ( Figure 5c , right panel). These results indicated that FOXM1 is one of the downstream targets of FLJ10540 in human cancer cells. Elevated MMP-2 activity by FOXM1 and FLJ10540 affects cell migration and invasion in oral cancer cells It has been reported that overexpressed FOXM1 can increase MMP-2 expression and enhance the invasion of glioma cells (Dai et al., 2007) . To determine the effect of an increased FOXM1 expression on MMP-2 activity, the protein amount and enzymatic activity of MMP-2 were measured by western blotting and gelatin zymography, using FaDu/FOXM1 and FaDu/vehicle transfectants. As shown in the left panel of Figure 6a , compared with the vehicle control, FOXM1 overexpression enhanced the protein expression and activity of MMP-2. However, the MMP-9 expression level was barely detectable, regardless of FOXM1 overexpression (data not shown). Similarly, the ectopic expression of FOXM1 increased the expression of the MMP-2 protein, but not of FLJ10540, in a Flag-FOXM1 dosedependent manner in HEK293T cells (Figure 6a, right  panel) . Moreover, the knockdown of FOXM1 protein expression by FOXM1 siRNA not only significantly decreased the activity and protein expression of MMP-2 but also inhibited the migratory and invasive ability of FaDu cancer cells (Figure 6b ). To further investigate the role of FOXM1 in regulating MMP-2 transcription, we determined whether FOXM1 could regulate MMP-2 promoter activity. A cotransfection of MMP-2 promoter-luciferase constructs with Flag-FOXM1 or with vehicle control into HEK293T cells showed an increase in the MMP-2 promoter activity in Flag-FOXM1 dosedependent transfectants as compared with that in vehicle control (Figure 6c, left panel) . Conversely, the MMP-2 promoter activity was reduced when FOXM1 was depleted by FOXM1 siRNAs (Figure 6c, right panel) . To further explore whether an induced MMP-2 by FOXM1 overexpression could affect the cell migration and invasion in human oral cancer cells, we used siRNA to inhibit the endogenous MMP-2 expression and assayed the migratory and invasive ability of FaDu/ vehicle and FaDu/FOXM1 cells. The results revealed that FOXM1 seems to promote migration and invasion in oral cancer cells by increasing MMP-2 expression ( Figure 6d) . Next, to investigate the clinical significances of FOXM1 and MMP-2 individually in OCSCC, an immunohistochemical analysis was carried out and the correlation with patient prognosis was estimated. An overall survival analysis using the Kaplan-Meier method and univariate analysis revealed that the prognosis of those patients with a strong tumor expression of FOXM1 or MMP-2 ( þ þ / þ þ þ ) was significantly poorer than that of patients with a negative or weak tumor FOXM1 or MMP-2 expression (À/ þ ) (Po0.001) (Table 2 and Figure 6e) .
The results from the overexpression or knockdown of FLJ10540 and FOXM1 (Figures 5 and 6 ) raised the possibility that FOXM1 might promote MMP-2 overexpression through an enforced FLJ10540 expression to encourage the motility of cancer cells. To test this hypothesis, the protein amount and enzymatic activity Figure 6c , the promoter activity of MMP-2 was increased in Flag-FLJ10540 dose-dependent transfectants compared with that in vehicle control in HEK293T cells (Figure 7b, left panel) . The MMP-2 promoter activity was reduced by depleting the endogenous FLJ10540 expression (Figure 7b , right panel). Moreover, the knockdown of the MMP-2 protein expression by MMP-2-siRNA not only significantly decreased the MMP-2 protein but also inhibited the migratory and invasive ability in FaDu/FLJ10540 transfectants (Figure 7c ). These results support the idea that enhanced oral cancer cell motility was regulated by FLJ10540-FOXM1-elicted MMP-2 overexpression and activation.
FLJ10540 overexpression is correlated with FOXM1 and MMP-2 expression in aggressive OCSCC specimens To confirm the clinical relevance of our in vitro observations regarding the regulation of FOXM1 and MMP-2 expression by FLJ10540, 100 samples from patients with aggressive OCSCC were examined by immunohistochemical staining. Examples of weak and strong staining for FLJ10540, FOXM1 and MMP-2 are shown (Figure 7d, upper panel) . Both FLJ10540 and FOXM1 immunoreactivities were in the cytoplasmic and nuclear compartments. However, MMP-2 was only localized in the cytoplasm. Furthermore, by immunofluorescence approach, FLJ10540 and FOXM1 were colocalized in the tumor tissues of OCSCC specimens (Figure 7d, bottom panel) . Similarly, the same results were also found in FaDu and SCC25 oral cancer cell lines (data not shown). Next, we carried out western blot analyses using total protein extracts from seven tumor samples collected from patients with aggressive OCSCC. As shown in Figure 7e , the FLJ10540 expression was correlated with the FOXM1 and MMP-2 expressions. The correlation between each paired immunohistochemical scores of FLJ10540, MMP-2 and FOXM1 was analysed by Spearman's rank tests. The result showed that there were positive correlations between FOXM1 and FLJ10540 (rho ¼ 0.815, Po0.001) and between MMP-2 and FLJ10540 (rho ¼ 0.786, Po0.001) ( Table 3) . Those patients with a high FLJ10540 score had a significantly higher FOXM1 and MMP-2 score. Taken together, these results suggest that there is a significant positive correlation among FLJ10540, FOXM1 and MMP-2 in aggressive human OCSCC.
Discussion
This study is the first to show the expression of FLJ10540 in a large cohort of primary OCSCC specimens. Our results indicate that the upregulated expression of FLJ10540 is associated with aggressiveness and poor prognosis of OCSCC patients. It is noteworthy that prognosis is not dependent on histological type but rather on the expression of FLJ10540. FLJ10540 positively correlated with a poor prognosis of oral cancer patients in tumor and nodal stages. As it is difficult to predict the prognosis of these patients, investigating the staining of FLJ10540 in an oral cancer cell may be helpful in determining the therapeutic strategy after a surgical operation. Next, an increased MMP-2 activity by FLJ10540 or FOXM1 is required for increasing cell motility, whereas the siRNA-based repression of endogenous FLJ10540 or FOXM1 expression decreases cell motility. Moreover, FLJ10540-induced cell metastasis is correlated with elevated FOXM1 and MMP-2 expressions in aggressive OCSCC specimens and in oral cancer cell lines. Our findings suggest that FLJ10540 is not only a good prognostic indicator of OCSCC but also a candidate for a molecular target of therapy for oral cancer.
There is little evidence to implicate that FLJ10540 is important in tumor development, invasion and in other aspects of cancer progression in human cancers, including oral cancer. We previously reported that FLJ10540 was overexpressed in hepatocellular carcinoma patients and it possessed a number of oncogenic characteristics, including anchorage-independent growth, enhanced cell growth at low serum levels and the induction of tumorigenesis in nude mice (Chen et al., 2007) . In addition, Sakai et al. (2006) also found that C10orf3 was overexpressed in clinical colon cancer tissues and it downregulated the tumor suppressor, TSG101, in a post-transcriptional manner (). Although the FLJ10540 expression is associated with cancer in humans, the causative role of FLJ10540 in tumor progression is unclear. Here, we showed that FLJ10540 was not only overexpressed in OCSCC (Figures 1 and 2 ) but was also correlated with the clinical characteristics of the tumor. The correlation of FLJ10540 with clinical tumor stage (Table 1) may be explained on a cellular level by the role of FLJ10540 in the growth regulation of cancer cells, whereas FLJ10540's correlation with nodal stage (Table 1) corresponds at the cellular level to its participation in the regulation of cell metastasis (Figures 3 and 4) .
FLJ10540 is a cell cycle-regulated protein that has been found in many locations (Fabbro et al., 2005; Martinez-Garay et al., 2006; Zhao et al., 2006) , which could be an indicator for the careful localization and distribution of FLJ10540 in human OCSCC specimens. Importantly, our immunohistochemical data showed that the intensity for FLJ10540 staining of most of the tumors and of adjacent non-cancerous tissues was mainly localized in the cytoplasm compared with that found in the nucleus of the tumor (B15-20%) and in the adjacent non-tumor tissues (B10-15%). Moreover, only tumor tissues had possessed the punctate staining of FLJ10540 in the cytoplasm (B5-10%). Taken together, we suggested that FLJ10540 may play many significant and multiple roles in OCSCC and oral cancer cells.
Metastasis is a complex process that involves several steps, including decreased adhesion, increased motility and proteolysis. The MMPs have emerged as key factors involved in both local growth and distant metastasis in a variety of tumors. The MMPs may exist in different forms in biological samples, such as latent enzymes, active enzymes or in complexes with inhibitors, such as tissue inhibitor of metalloproteinases (TIMP) and membrane-type matrix metalloproteinase (MT-MMP). Our data suggest that one mechanism by which FLJ10540 may promote tumor cell migration and invasion is through the increased expression and proteolytic activity of MMP-2, which specifically degrades the basement membrane (Figure 7a ). The MMP-2 has been suggested to play critical roles in oral cancer migration and metastasis (Munshi et al., 2002; Ruokolainen et al., 2006; Patel et al., 2007) , and the upregulation of MMP-2 has been associated with a poor prognosis in oral cancer patients (Ruokolainen et al., 2006) . The activation of proMMP-2 has been considered to be a particularly important step in tumor invasion (Itoh et al., 2001) . Biochemical studies have shown that TIMP-2 may have a role in controlling MMP-2 activation through a tri-molecular complex formed from pro-MMP-2, TIMP-2 and MT1-MMP (Strongin et al., 1995; Butler et al., 1998; Kinoshita et al., 1998) . This raised the possibility that an enhanced MMP-2 activity by FLJ10540/FOXM1 could affect the expression of MT1-MMP and TIMP-2 in oral cancer cells. In fact, the overexpression of FLJ10540 or FOXM1 enhanced the mRNA and protein expressions of MT1-MMP and TIMP-2, whereas the inhibition of FLJ10540 or of the FOXM1 protein expression by siRNA reduced the mRNA and protein expressions of MT1-MMP and TIMP-2 (data not shown). However, TIMP-1 was not changed in both assay systems. This finding indicated that the induced TIMP-2 and MT1-MMP overexpression could be promoted by FLJ10540, suggesting that the MMP-2/TIMP-2/MT1-MMP complex may be important in contributing towards FLJ10540-elicited oral cancer cell metastasis (manuscript in preparation). The role of mitogen-activated protein kinases, such as ERK (extracellular signal-regulated kinase), in the regulation of MMP-2 expressions in carcinoma cells has been well studied. It has been shown that the activation of p-ERK1/2 may lead to an enhancement in the expression of MMP-2, as well as in the invasion of tumor cells (Rao, 2003; Lev et al., 2004) . However, p-ERK has no significant difference between FLJ10540-stable transfectants and vehicle control (data not shown).
We used and re-arranged Gaffney's gene expression microarray dataset (Ginos et al., 2004) , and found that two candidates, FOXM1 and MMP-2, were highly positively correlated with the mRNA expression level of FLJ10540 in head and neck cancer patients. It has been reported that FOXM1 is not only important in the oncogenesis of several malignancies, including that of cervical cancer (Chan et al., 2008) , lung cancer (Kim et al., 2006) , breast cancer (Madureira et al., 2006) and liver cancer (Kalinichenko et al., 2004) , but it also enhances the invasion of cancer cells through MMP-2 expression, such as glioma cells (Dai et al., 2007) . Here, we used the FLJ10540 overexpression and siRNAknockdown systems and showed that increasing the FLJ10540 expression could upregulate the FOXM1/ MMP-2 expression in FLJ10540 transfectants or in transient transfected cells, whereas inhibiting the FLJ10540 expression significantly downregulated the FOXM1/MMP-2 expression in FLJ10540-depleted cells (Figures 5 and 7) . Furthermore, the ectopic expression of FOXM1 in FaDu cells resulted in increases in endogenous MMP-2, but not in endogenous FLJ10540 proteins in a dose-dependent manner; whereas the inhibition of the FOXM1 expression by siRNA could only downregulate the MMP-2 expression and oral cancer cell motility (Figures 6a and b) . The mechanisms responsible for the overexpression of FOXM1 in malignant cancer cells are still not clear. This is the first study to unravel that one of the important upstream regulators of FOXM1 and MMP-2 may be regulated by an oncoprotein, FLJ10540, in oral cancer cells. Finally, western blotting, immunohistochemical and immunofluorescence analyses showed a significant correlation that the overexpression of FLJ10540 not only elevated the expression of MMP-2 and FOXM1 but also colocalized with FOXM1 in aggressive OCSCC specimens.
Importantly, besides FLJ10540, it is also the first time that the participation of FOXM1 in the invasive cancer cell of OCSCC has been illustrated (Figures 7d and e) . Therefore, our results show that an increased MMP-2 expression could be attributed to an increased expression of FOXM1, which was regulated by FLJ10540 for promoting cancer cell metastasis in OCSCC.
In summary, our findings suggest that FLJ10540 upregulation is a common abnormality in OCSCC and may play a role in its progression. We showed that FLJ10540 overexpression is correlated with tumor progression and shortened survival. Furthermore, the overexpression of FLJ10540 in malignant oral cancer cells contributes to the overexpression of FOXM1 and of MMP-2 and, hence, to the induction of oral cancer cell migration and invasion. These results strongly suggest that an FLJ10540 expression is critical for the invasiveness of malignant oral cancer cells. Future studies of the physiological targets of FLJ10540 and its potential role in the pathogenesis of OCSCC will facilitate the development of novel therapeutic strategies for the treatment of OCSCC. 
Materials and methods
Patients and tumor samples
Statistical analysis
Several clinicopathological factors were evaluated, including sex, age (59 versus 60 years), T1, T2 versus T3, T4 stage, N status and TNM stage. Fisher's exact test was used to evaluate the correlation between the clinicopathological variables and the expression of FLJ10540. A P-value o0.05 was considered to be significant in all analyses. The clinicopathological variables and the expression of FLJ10540 were taken into account for the analysis of survival on the basis of the KaplanMeier method; statistical significance, defined as a P-value o0.05, was assessed by the log-rank test. To determine the effect of particular prognosis factors on survival, a multivariate analysis was carried out according to Cox's regression model.
Immunoblot analysis
For tissue protein extraction, frozen samples were homogenized in RIPA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate and 0.1% SDS). The protein concentration in each sample was estimated by BioRad Protein Assay (Bio-Rad, Hercules, CA, USA). Immunoblotting was carried out according to standard procedures. The antibodies used in this study include polyclonal antibodies against FLJ10540, FLJ10540 (Abnova), HA (3F10, Roche Biochemicals, Indianapolis, IN, USA), MMP-2, FOXM1 and b-actin (monoclonal; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The first antibodies were detected by incubation with secondary antibodies conjugated to horseradish peroxidase (Bio/Can Scientific, Mississauga, ON, Canada) and developed using Western Lighting Reagent (Perkin Elmer Life Sciences, Shelton, CT, USA). The proteins were explored by X-ray films.
Cell culture, transient transfection and the establishment of stable clones All cell culture-related reagents were purchased from Gibco-BRL (Grand Island, NY, USA). FaDu, SCC25, MDCK and HEK293T cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 100 U/ml penicillin and streptomycin (Gibco-BRL). HA-vector (pcDNA3.1), HA-FLJ10540, HA-FOXM1, Flag-vector (pCMV2), Flag-FLJ10540 and Flag-FOXM1 were transiently transfected into cancer cells using Lipofectamine (Invitrogen, Grand Island, NY, USA), according to the manufacturer's instructions. FaDu, SCC25 and MDCK cells stably expressing FLJ10540 or FaDu expressing FOXM1 were selected with 400 mg/ml G418 (Calbiochem Novabiochem, San Diego, CA, USA). The cells were then harvested and analysed for exogenous FLJ10540 or FOXM1 expression by western blotting. Four double-stranded synthetic RNA oligomers (5 0 -GGGAGAAATTGCACACTTA tt-3 0 and 5 0 -GGACTTTT AGCAAAGATCTtt-3 0 ; Ambion) deduced from human FLJ10540, (5 0 -CUCUUCUCCCUCAGAUAUAtt-3 0 ) deduced from human FOXM1, (5 0 -GGAGAGCUGCAACCUG UUUGtt-3 0 ) deduced from human MMP-2 and one negative control siRNA (#4611G; Ambion, Ambion, Austin, TX, USA) were used in the siRNA experiments.
Gelatin zymography FLJ10540 and FOXM1-stable clones or siFLJ10540 and siFOXM1 transfectants were used to analyse the activities of MMP-2 and MMP-9. Conditioned media were prepared by incubating the cells in serum-free media for 24 h. Equal volumes of the conditioned media were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, with gels containing 0.1% gelatin. The gels were stained to visualize the level of gelatinase activity (Park et al., 2002) .
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